Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer

Klaus Brasso, Frederik Birkebæk Thomsen, Kasper Drimer Berg, Martin Andreas Røder, Peter Iversen

    Abstract

    Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.
    Bidragets oversatte titelNew endocrine treatments prolong survival of patients with castration-resistant prostate cancer.
    OriginalsprogDansk
    TidsskriftUgeskrift for Laeger
    Vol/bind175
    Udgave nummer40
    Sider (fra-til)2328-2332
    Antal sider5
    ISSN0041-5782
    StatusUdgivet - 30 sep. 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater